4-4-difluoro-4-bora-3a-4a-diaza-s-indacene and Niemann-Pick-Disease--Type-C

4-4-difluoro-4-bora-3a-4a-diaza-s-indacene has been researched along with Niemann-Pick-Disease--Type-C* in 2 studies

Other Studies

2 other study(ies) available for 4-4-difluoro-4-bora-3a-4a-diaza-s-indacene and Niemann-Pick-Disease--Type-C

ArticleYear
Methyl-β-cyclodextrin restores impaired autophagy flux in Niemann-Pick C1-deficient cells through activation of AMPK.
    Autophagy, 2017, Aug-03, Volume: 13, Issue:8

    The drug 2-hydroxypropyl-β-cyclodextrin (HPβCD) reduces lysosomal cholesterol accumulation in Niemann-Pick disease, type C (NPC) and has been advanced to human clinical trials. However, its mechanism of action for reducing cholesterol accumulation in NPC cells is uncertain and its molecular target is unknown. We found that methyl-β-cyclodextrin (MβCD), a potent analog of HPβCD, restored impaired macroautophagy/autophagy flux in Niemann-Pick disease, type C1 (NPC1) cells. This effect was mediated by a direct activation of AMP-activated protein kinase (AMPK), an upstream kinase in the autophagy pathway, through MβCD binding to its β-subunits. Knockdown of PRKAB1 or PRKAB2 (encoding the AMPK β1 or β2 subunit) expression and an AMPK inhibitor abolished MβCD-mediated reduction of cholesterol storage in NPC1 cells. The results demonstrate that AMPK is the molecular target of MβCD and its activation enhances autophagy flux, thereby mitigating cholesterol accumulation in NPC1 cells. The results identify AMPK as an attractive target for drug development to treat NPC.

    Topics: AMP-Activated Protein Kinases; Autophagosomes; Autophagy; beta-Cyclodextrins; Boron Compounds; Cholesterol; Endocytosis; Enzyme Activation; Enzyme Activators; Humans; Kinetics; Models, Biological; Niemann-Pick Disease, Type C; Protein Kinase Inhibitors

2017
A high-content RNAi-screening assay to identify modulators of cholesterol accumulation in Niemann-Pick type C cells.
    Assay and drug development technologies, 2010, Volume: 8, Issue:3

    Niemann-Pick disease type C (NPC) is an inherited lipid storage disorder characterized by a defect in intracellular trafficking of exogenous cholesterol and glycosphingolipids. A goal for therapeutic treatment of NPC is to decrease/normalize cholesterol accumulation. We developed a functional genomics-based assay, combining high-throughput RNA interference (HT-RNAi) screening with high-content fluorescence imaging to identify specific genes in NPC cells that will result in more normal cholesterol levels in the diseased cells. Conditions for siRNA tranfections were optimized for 2 NPC fibroblast cell lines (GM03123, GM18453) and a normal fibroblast cell line (GM05659). RNAi screening was done using a focused-set siRNA library targeting 40 cholesterol trafficking-associated genes, knowledge mined from the existing literature on NPC disease, and/or their association with NPC1/NPC2 genes. We utilized filipin staining as a measure of cholesterol accumulation in fixed NPC cells. Data analysis of these screens confirmed several genes including LDLR and RAB9A that reduced cholesterol content in NPC cells. Nine genes were validated using filipin staining to detect unesterified cholesterol as well as cholesteryl BODIPY esters to study lipid trafficking. Gene silencing was also confirmed using qRT-PCR. Our results show that this technology can be applied to larger screens to identify genes responsible for lipid accumulation and/or trafficking in NPC disease, which could be instrumental in developing innovative therapies for individuals afflicted with NPC disease.

    Topics: Boron Compounds; Cell Line; Cholesterol; Cholesterol Esters; Data Interpretation, Statistical; Drug Evaluation, Preclinical; Fibroblasts; Fluorescent Dyes; Genomics; Humans; Image Processing, Computer-Assisted; Niemann-Pick Disease, Type C; RNA Interference; RNA, Small Interfering; Software

2010